Core Viewpoint - A class action lawsuit has been filed against Sana Biotechnology, Inc. for allegedly misleading investors regarding its financial stability and the potential of its product candidates [1][2]. Group 1: Allegations Against Sana Biotechnology - The lawsuit claims that Sana was at significant risk of having insufficient funds to maintain operations and advance its product candidates [2]. - Specific product candidates, including SC291 in oncology, SC379, and SG299, were reportedly less promising than what the company had communicated to investors [2]. - To conserve cash and focus on more promising candidates, Sana was likely to reduce funding for or discontinue certain projects and significantly cut its workforce [2]. - As a result, the company allegedly overstated its financial capacity to sustain operations and advance its product pipeline [2]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers with the court by May 20, 2025 [3]. - Participation in the class action is not required to be eligible for recovery; shareholders can remain absent class members if they choose [3]. Group 3: About Robbins LLP - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4].

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 17, 2024, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 20, 2025. SO WHAT: If you purchased Sana securities during the Class Period ...

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/sana-biotechnology-inc-loss-submission-form/?id=138493&from=3 CLASS PERI ...

Core Viewpoint - A class action lawsuit has been filed against Sana Biotechnology, Inc. for misleading statements regarding its financial health and product candidates during the specified Class Period from March 17, 2023, to November 17, 2024 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Sana was at significant risk of insufficient funds to maintain operations and advance product candidates [5]. - It alleges that the product candidates SC291, SC379, and SG299 were less promising than represented, and that funding for these candidates would likely be decreased or discontinued [5]. - Defendants are accused of overstating Sana's financial capacity, leading to materially false and misleading public statements [5]. Group 2: Participation Information - Investors who purchased Sana securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties must act before May 20, 2025, to serve as lead plaintiff [3][6]. - The Rosen Law Firm encourages investors to select qualified counsel with a successful track record in securities class actions [4].

Core Viewpoint - A class action lawsuit has been filed against Sana Biotechnology, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from March 17, 2023, to November 4, 2024, seeking damages for affected investors [1]. Company Overview - Sana Biotechnology, Inc. is a biotechnology company focused on developing ex vivo and in vivo cell engineering programs aimed at addressing unmet treatment needs in various therapeutic areas, including oncology, diabetes, CNS disorders, and autoimmune diseases [3]. Financial and Operational Claims - Throughout the Class Period, company officials claimed that Sana had the financial capacity to maintain operations and advance product candidates, including SC291, SC379, and SG299, highlighting promising preclinical and clinical results [4]. - The complaint alleges that the company misrepresented its financial health, stating that it was at significant risk of insufficient funds to support operations and product development, and that the product candidates were less promising than claimed [5]. Recent Developments - On October 10, 2023, Sana announced a reduction in spending on its fusogen platform and a 29% headcount reduction, aiming to keep its 2024 operating cash burn below $200 million, which led to an 8.95% drop in stock price [6]. - On November 4, 2024, the company announced the suspension of development for SC291 and SC379, reallocating resources to its type 1 diabetes program, which resulted in a 9.84% decline in stock price [7][8].

Core Viewpoint - A class action lawsuit has been filed against Sana Biotechnology, Inc. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its financial health and product candidates [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased securities between March 17, 2023, and November 4, 2024, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against the Company - The complaint alleges that Sana Biotechnology made false and misleading statements about its funding and product candidates [4]. - The company reportedly faced significant risks regarding insufficient funding to maintain operations and advance product candidates [4]. - It is claimed that several product candidates were less promising than represented, leading to potential funding cuts and layoffs to preserve cash for more promising candidates [4]. - The company's public statements were deemed false and materially misleading, resulting in investor damages when the truth emerged [4].

Company Overview - Sana Biotechnology, Inc. (NASDAQ: SANA) is a biotechnology company focused on producing engineered cells to repair or replace damaged cells that cause diseases [1] - The company explores both ex vivo and in vivo approaches to develop new therapies [1] Technology and Research - For ex vivo applications, Sana leverages its proprietary technology [1]

Core Viewpoint - A class action lawsuit has been filed against Sana Biotechnology, Inc. for allegedly misleading investors regarding its financial stability and product development capabilities [1][2]. Group 1: Allegations and Financial Concerns - The lawsuit claims that Sana was at significant risk of having insufficient funds to maintain operations and advance its product candidates [2]. - Specific product candidates, including SC291 in oncology, SC379, and SG299, were reportedly less promising than what the company had communicated to investors [2]. - To conserve cash and focus on more promising candidates, Sana was likely to reduce funding for or discontinue certain projects and significantly cut its workforce [2]. - The defendants are accused of overstating Sana's financial capacity, which led to a decline in stock price when the truth was revealed [2]. Group 2: Legal Proceedings - Shareholders interested in serving as lead plaintiffs must file their papers by May 20, 2025 [3]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [3]. Group 3: Company Background - Robbins LLP is a recognized leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [4].

Core Viewpoint - A shareholder class action lawsuit has been filed against Sana Biotechnology, alleging misleading statements and failure to disclose material facts regarding the company's financial health and product prospects [1]. Group 1: Allegations in the Lawsuit - The lawsuit claims that Sana was at significant risk of having insufficient funds to maintain its current operations and advance its product candidates [1]. - It is alleged that the product candidates SC291 in oncology, SC379, and SG299 were less promising than what the company had communicated to investors [1]. - The lawsuit suggests that to preserve cash and focus on more promising candidates, Sana was likely to decrease funding for or discontinue SC291, SC379, and SG299, as well as significantly reduce its workforce [1]. - Consequently, the defendants are accused of overstating Sana's financial capacity to sustain operations and advance existing product candidates [1].

Core Viewpoint - A securities class action lawsuit has been filed against Sana Biotechnology, Inc. for allegedly making false and misleading statements regarding its financial health and product candidates, impacting investors during the specified class period [1][2]. Group 1: Allegations Against the Company - The lawsuit claims that the defendants failed to disclose significant risks regarding Sana's financial stability and the viability of its product candidates [2]. - Specific allegations include that Sana was at risk of insufficient funds to maintain operations and advance product candidates, and that certain products were less promising than previously stated [2]. - The complaint also suggests that to conserve cash, Sana was likely to reduce funding for certain projects and significantly cut its workforce, which was not disclosed to investors [2]. Group 2: Impact on Investors - The complaint indicates that the misleading statements led to a decline in Sana's stock price, resulting in damages to investors [3]. - Investors who acquired shares during the class period are encouraged to contact the law firm representing the class action before the lead plaintiff motion deadline [4].